An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
KORU Medical Systems (NASDAQ: KRMD) has joined the Subcutaneous Drug Development & Delivery Consortium, positioning itself as a pioneer among device companies. This membership allows KORU Medical to collaborate with top industry experts to tackle challenges in the SC field, enhancing drug delivery systems. The Consortium aims to address unmet medical needs and improve patient outcomes through evidence-based communication. KORU Medical, known for its Freedom System used by over 25,000 patients, brings considerable expertise in subcutaneous therapy, especially for volumes above 5mL.
Positive
KORU Medical joins the Subcutaneous Drug Development & Delivery Consortium, enhancing collaboration with industry experts.
Membership allows KORU Medical to influence SC drug delivery, improving patient outcomes.
KORU Medical has established itself as the market leader for biologics above 10mL, bringing critical expertise to the Consortium.
Negative
None.
MAHWAH, N.J.--(BUSINESS WIRE)--
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its membership in the Subcutaneous (SC) Drug Development & Delivery Consortium (the “Consortium”), making it one of the first device companies to be added to the Consortium.
“The Consortium creates an important forum to identify and address key challenges and opportunities across the SC field,” said Linda Tharby, KORU Medical’s President and CEO. “Key industry experts can collaborate on issues at the clinical, regulatory, and commercial level and work towards advancing the SC market and creating the best outcomes for patients. I am excited for KORU Medical’s membership as one of the first device companies and look forward to advancing SC drug delivery.”
The Consortium was convened in 2018 as a community of well-recognized industry experts with decades of experience in the pharmaceutical drug delivery, device development, and commercialization space. The Consortium was built upon a strong desire for clear and transparent evidence-based communication of existing SC technologies and information. The Consortium’s mission is to identify current and future unmet medical needs within a dynamic SC drug delivery and development environment to transform patient care and improve patient outcomes. As a member, KORU Medical will contribute to advancing understanding of patient preference for SC therapy and the clinical trial strategy and technology for high-volume SC drugs. KORU Medical was one of the first companies to develop technology for SC biologics with volumes above 5mL, and its Freedom System is used by over 25,000 patients today to receive SC therapy. KORU Medical is established as the market leader in above 10mL and will bring this deep expertise in patient experience and subcutaneous injection technology to the Consortium.
About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
What does KORU Medical's membership in the SC Consortium mean for KRMD shareholders?
KORU Medical's membership in the SC Consortium enhances its collaboration with industry experts, potentially leading to improved products and services that can positively impact shareholder value.
When did KORU Medical join the Subcutaneous Drug Development & Delivery Consortium?
KORU Medical announced its membership in the Consortium on a recent business press release.
How many patients use KORU Medical's Freedom System?
Over 25,000 patients currently use KORU Medical's Freedom System for subcutaneous therapy.
What is the primary focus of KORU Medical's products?
KORU Medical focuses on developing innovative home infusion solutions to improve quality of life for patients.
